Metabolism of dl-Praeruptorin A in Rat Liver Microsomes using HPLC-Electrospray Ionization Tandem Mass Spectrometry

被引:13
作者
Ruan, Hang [2 ]
Zhang, Zhen [2 ]
Liang, Xin-fang [1 ]
Fu, Yan [1 ]
Su, Mei-qin [1 ]
Liu, Qi-lin [1 ]
Wang, Xiu-min [1 ]
Zhu, Xuan [1 ]
机构
[1] Xiamen Univ, Coll Pharmaceut Sci, Xiamen 361005, Peoples R China
[2] Xiamen Univ, Coll Med, Xiamen 361005, Peoples R China
关键词
dl-Praeruptorin A; Cytochrome P450 isoforms; Metabolites; Rat liver microsomes; In vitro; HPLC-ESI-MSn; LIQUID-CHROMATOGRAPHY; PEUCEDANUM-PRAERUPTORUM; INHIBITION; COUMARIN; DRUG; CYTOCHROME-P-450; PHARMACOKINETICS; EXPRESSION; OXIDATION; INDUCERS;
D O I
10.1007/s12272-011-0811-y
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
dl-Praeruptorin A (Pd-Ia) is the major active constituent of the traditional Chinese medicine Peucedanum praeruptorum Dunn. Recently it has been identified as a novel agent in the treatment and prevention of cardiovascular diseases. Accordingly, we investigated the metabolism of Pd-Ia in rat liver microsomes. The involvement of cytochrome P450 (CYP) and CYP isoforms were identified using a CYP-specific inhibitor (SKF-525A), CYP-selective inhibitors (a-naphthoflavone, metyrapone, fluvastatin, quinidine, disulfiram, ketoconazole and ticlopidine) and CYP-selective inducers (phenobarbital, dexamethasone and beta-naphthoflavone). Residual concentrations of the substrate and metabolites were determined by HPLC, and further identified by their mass spectra and chromatographic behavior. These experiments showed that CYP450 is involved in Pd-Ia metabolism, and that the major CYP isoform responsible is CYP3A1/2, which acts in a concentration-dependent manner. Four Pd-Ia metabolites (M1, M2, M3, and M4) were detected after incubation with rat liver microsomes. Hydroxylation was the primary metabolic pathway of Pd-Ia, and possible chemical structures of the metabolites were identified. Further research is now needed to link the metabolism of Pd-Ia to its drug-drug interactions.
引用
收藏
页码:1311 / 1321
页数:11
相关论文
共 32 条
[1]   Identification of the cytochromes P450 that catalyze coumarin 3,4-epoxidation and 3-hydroxylation [J].
Born, SL ;
Caudill, D ;
Fliter, KL ;
Purdon, MP .
DRUG METABOLISM AND DISPOSITION, 2002, 30 (05) :483-487
[2]   EFFECTS OF DISULFIRAM ON HEPATIC P450IIE1, OTHER MICROSOMAL-ENZYMES, AND HEPATOTOXICITY IN RATS [J].
BRADY, JF ;
XIAO, F ;
WANG, MH ;
LI, Y ;
NING, SM ;
GAPAC, JM ;
YANG, CS .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1991, 108 (02) :366-373
[3]  
CHANG H, 2000, J CHINA MED U, V29, P84
[4]  
Chang TH, 2002, ACTA PHARMACOL SIN, V23, P769
[5]   Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous ipriflavone in rats [J].
Chung, HJ ;
Choi, YH ;
Kim, SH ;
Lee, MG .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2006, 58 (04) :449-457
[6]   Metabolism of an anionic fluorescent dye, 1-anilino-8-naphthalene sulfonate (ANS) by rat liver microsomes [J].
Chung, YB ;
Bae, WT ;
Han, K .
ARCHIVES OF PHARMACAL RESEARCH, 1998, 21 (06) :677-682
[7]   Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition [J].
Dresser, GK ;
Spence, JD ;
Bailey, DG .
CLINICAL PHARMACOKINETICS, 2000, 38 (01) :41-57
[8]  
Gibbs MA, 1999, DRUG METAB DISPOS, V27, P596
[9]  
Goshman L., 1999, J PHARM SOC WIS, V5, P23
[10]  
HSU A, 1999, ARCH PHARM RES, V22, P324